Physician profile
Mark D Bedard
NPI 1154649861
$4,838.52
in general payments reported to CMS, 2019-2025
34 companies · $787 in 2025
The $787 reported for 2025 was more than what 97% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $780 · 2020: $369 · 2021: $937 · 2022: $675 · 2023: $566 · 2024: $725 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,078.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,078.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neos Therapeutics, Lp | $615.68 | 2019-2023 | Cotempla Xr-Odt |
| Supernus Pharmaceuticals, INC. | $506.43 | 2021-2025 | Qelbree, Qelbree |
| Ironshore Pharmaceuticals INC. | $445.29 | 2019-2024 | Jornay Pm |
| Glaxosmithkline, LLC. | $382.48 | 2019-2025 | Bexsero, Rotarix, Pediarix |
| Merck Sharp & Dohme LLC | $365.27 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Corium, LLC | $362.59 | 2022-2025 | Azstarys |
| Pfizer INC. | $289.12 | 2019-2025 | |
| Tris Pharma INC | $262.04 | 2019-2024 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $212.40 | 2019-2022 | |
| Cranial Technologies, INC | $179.26 | 2020-2025 | Doc Band |
| Kaleo, INC. | $168.78 | 2019-2022 | |
| Collegium Pharmaceutical, INC. | $149.74 | 2025 | Jornay Pm |
| Verrica Pharmaceuticals INC. | $143.11 | 2024-2025 | Ycanth |
| Sanofi Pasteur INC. | $128.22 | 2021-2025 | |
| Genzyme Corporation | $93.80 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $86.47 | 2019 | |
| Adlon Therapeutics L.P. | $54.99 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $49.84 | 2025 | |
| Hologic Sales and Service, LLC | $33.93 | 2019-2023 | Aptima |
| Cipher Pharmaceuticals US LLC | $29.88 | 2025 | Spinosad, Natroba |
| Kowa Pharmaceuticals America, INC. | $27.98 | 2024-2025 | Zoryve |
| Seqirus USA INC | $25.95 | 2024 | Flucelvax |
| Mylan Pharmaceuticals INC. | $25.85 | 2019 | |
| Lnhc, INC | $23.60 | 2025 | Zelsuvmi |
| Noven Therapeutics, LLC | $23.00 | 2024 | Xelstrym |
| Ars Pharmaceuticals Operations, INC. | $19.26 | 2025 | Neffy |
| Astrazeneca Pharmaceuticals Lp | $19.12 | 2024 | Flumist Quadrivalent |
| Neurelis, INC. | $18.50 | 2021 | |
| Alk-Abello, INC | $18.23 | 2025 | Ragwitek, Grastek, Odactra |
| Aytu Biopharma, INC. | $18.04 | 2021 | |
| Phadia US INC. | $17.66 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $16.05 | 2019 | |
| Sobi, INC | $13.17 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Bedard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.